

Accretive Health, Inc.
Form NT 10-K
March 04, 2013

SEC FILE NUMBER

001-34746
CUSIP NUMBER

00438V103

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q

 Form 10-D Form N-SAR Form N-CSR

For Period Ended: December 31, 2012

Transition Report on Form 10-K
 Transition Report on Form 20-F
 Transition Report on Form 11-K
 Transition Report on Form 10-Q
 Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I REGISTRANT INFORMATION

Accretive Health, Inc.

Full Name of Registrant

Former Name if Applicable

401 North Michigan Avenue, Suite 2700

Address of Principal Executive Office (*Street and Number*)

Chicago, IL 60611

City, State and Zip Code

PART II RULE 12B-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Accretive Health, Inc. (the Company) has determined that it is unable to file its Annual Report on Form 10-K for the year ended December 31, 2012 within the prescribed time period without unreasonable effort or expense for the following reason.

As discussed in the Company's press release filed with the Securities and Exchange Commission (the SEC) on February 26, 2013, the Company has been evaluating the manner in which it recognizes revenue for its revenue cycle management agreements. On March 4, 2013, the Audit Committee of the Board of Directors (the Audit Committee) determined that the Company will restate its financial statements. The Audit Committee made this determination following consultation with and upon the recommendation of management and following consultation with Ernst & Young LLP. The Company believes, based on information available to date, that such restatement will have no impact on total revenue recognized over the life of a contract or the timing or magnitude of cash flow from operations, and will defer the timing of revenue recognition and lead to an increase in deferred revenue or other liabilities reported in prior periods. Because the Company is in the process of restating its financial statements as described above, the Company has not been able to complete its financial statements for the year ended December 31, 2012 and, accordingly, is unable to file its Annual Report on Form 10-K within the prescribed time period. The Company will, on or before March 8, 2013, file a Current Report on Form 8-K with the SEC to report the Audit Committee's determination described above.

As a result of the Company's inability to file its Annual Report on Form 10-K within the prescribed time period, the Company anticipates that it will receive a notice from the New York Stock Exchange (the NYSE) indicating that the Company is not currently in compliance with continued listing requirements under the timely filing criteria outlined in Section 802.01E of the NYSE-Listed Company Manual. This notice is considered routine practice under NYSE rules when a listed company does not make a timely filing with the SEC. In accordance with NYSE rules, upon receipt of this notice from the NYSE, the Company will be required to issue a press release to announce receipt of the notice; within four business days after receipt of the notice, the Company will also be required to file a Current Report on Form 8-K with the SEC to report receipt of the notice. The NYSE has informed the Company that under NYSE rules the Company will have until September 13, 2013 to file its Form 10-K. Until the Company files its Form 10-K, the Company's common stock will remain listed on the NYSE under the trading symbol AH, but the NYSE has informed the Company that under NYSE rules LF will be added to the Company's trading symbol beginning on March 20, 2013 to indicate the Company's late-filing status. The Company can regain compliance with the NYSE listing standards at any time prior to September 13, 2013 once it files its Form 10-K with the SEC.

PART IV OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

John T. Staton
(Name)

(312)
(Area Code)

324-7820
(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

As discussed in the Company's press release filed with the SEC on February 26, 2013, the Company has been evaluating the manner in which it recognizes revenue for its revenue cycle management agreements. As described above, on March 4, 2013, the Audit Committee determined that the Company will restate its financial statements. The Company believes, based on information available to date, that such restatement will have no impact on total revenue recognized over the life of a contract or the timing or magnitude of cash flow from operations, and will defer the timing of revenue recognition and lead to an increase in deferred revenue or other liabilities reported in prior periods.

Safe Harbor Statement

This Form 12b-25 contains forward-looking statements, including the Company's statements regarding the anticipated consequences of the restatement of the Company's financial statements described above. All forward-looking statements contained in this Form 12b-25 involve risks and uncertainties. Our actual results and outcomes could differ materially from those anticipated in these forward-looking statements as a result of various factors, including the possibility that any restatement that may be required could have unanticipated consequences and the factors set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, filed with the SEC on November 8, 2012, under the heading Risk Factors. The words strive, objective, anticipates, believes, estimates, expects, intends, may, plans, projects, expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, actual results, performance, financial condition, or events may vary materially and adversely from those anticipated, estimated, or expected.

All forward-looking statements included in this Form 12b-25 are expressly qualified in their entirety by these cautionary statements. We wish to caution readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the uncertainties and factors described above, as well as others that we may consider immaterial or do not anticipate at this time. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations may prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown uncertainties and factors, including those described above. The risks and uncertainties described above are not exclusive, and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition or relationships with customers and potential customers, may emerge from time to time. We assume no, and we specifically disclaim any, obligation to update, amend, or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our periodic reports that we file with or furnish to the SEC.

Accretive Health, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 4, 2013

By: /s/ John T. Staton
Name: John T. Staton
Title: Chief Financial Officer